Company News

bioMérieux is making a $5 million investment in InDevR, and will be the exclusive distributor in Europe of VaxArray®, a state-of-the-art vaccine quality control platform developed by the American company.

These certifications demonstrate the quality of our HR strategy and rewards the commitment of our HR teams who work every day to improve the employee experience at bioMérieux! The Top Employer seal also impacts our attractiveness by telling candidates that we care about our people!

bioMérieux takes a proactive, partnership-driven approach to combating AMR with diagnostic and data-driven solutions to improve stewardship efforts. To further this goal, bioMérieux created the AMS Centers of Excellence (CoE) designation awarded to hospitals around the world as a sign of a joint commitment to best AMS practices.

bioMérieux and NecstGen, collaborate to accelerate the development of Cell and Gene Therapies (CGT) through the provision of ‘state of the art’ and rapid quality and safety testing technologies that will allow safe and effective advanced therapeutics production.

For 20 years, bioMérieux and the Hospices Civils de Lyon (HCL) have been collaborating in an innovative public/private research partnership. Joined in 2016 by Claude Bernard Lyon 1 University, the three institutions are working to figure out the mechanisms of immunity in order to develop diagnostic tests.